Diabetes, Newly Diagnosed and Monitoring Panel
Use
This panel provides a comprehensive evaluation of key laboratory parameters in patients newly diagnosed with diabetes or during routine monitoring, aligning with American Diabetes Association (ADA) recommendations. It includes fasting glucose and hemoglobin A1c for glycemic control, fasting lipid profile for cardiovascular risk assessment, liver function tests for hepatic health, urinary albumin excretion (including spot urine albumin-to‑creatinine ratio) for nephropathy screening, and serum creatinine with estimated glomerular filtration rate (eGFR) for kidney function monitoring ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/about-our-tests/diabetes-pre-diabetes/newly-diagnosed-monitoring-panel?utm_source=openai)).
Special Instructions
Not provided.
Limitations
Not provided.
Methodology
Automated Analyzer
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
Not provided
